Brief: Timber Pharmaceuticals Announces All Control Study Sites Open And Enrolling Patients With Moderate To Severe Congenital Ichthyosis
01/07/2020 13:29
July 1 (Reuters) - Timber Pharmaceuticals Inc TMBR.A :
* TIMBER PHARMACEUTICALS ANNOUNCES ALL CONTROL STUDY SITES
OPEN
AND ENROLLING PATIENTS WITH MODERATE TO SEVERE CONGENITAL
ICHTHYOSIS
Source text for Eikon: ID:nGNX8GrVkm
Further company coverage: TMBR.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Trex Wind-Down
See all newsBrief: NYSE American To Suspend Trading Immediately In Timber Pharma
Brief: Timber Pharmaceuticals Receives Court Approval Of All “First Day” Motions To Support Business
Brief: NYSE American to Commence Delisting Proceedings Against Timber Pharmaceuticals
Brief: Timber Pharmaceuticals Says Prior To Filing Of Chapter 11 Case, Debtors Entered Into A "Stalking Horse" Asset Purchase Agreement
Brief: Timber Pharmaceuticals Inc Files For Voluntary Chapter 11 Bankruptcy - Court Filing